ArticleStatistics in medicine2017
Identifying a maximum tolerated contour in two-dimensional dose finding.
Article in Statistics in medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Concurrent dose-finding of a novel cancer drug with and without a second agent.Journal of clinical and translational science · 2023Article
- Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials.Statistics in biopharmaceutical research · 2022Article
- AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose finding trials.Journal of the Royal Statistical Society. Series C, Applied statistics · 2019Article
- Two-stage design for phase I-II cancer clinical trials using continuous dose combinations of cytotoxic agents.Journal of the Royal Statistical Society. Series C, Applied statistics · 2019Article
- Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events.Journal of the Royal Statistical Society. Series C, Applied statistics · 2017Article
- A design for phase I trials in completely or partially ordered groups.Statistics in medicine · 2017Article
- Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.Journal of biometrics & biostatistics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The majority of phase I methods for multi-agent trials have focused on identifying a single maximum tolerated dose combination (MTDC) among those being investigated. Some published methods in the area have been based on the notion that there is no unique MTDC and that the set of dose combinations with acceptable toxicity forms an equivalence contour in two dimensions. Therefore, it may be of interest to find multiple MTDCs for further testing for efficacy in a phase II setting. In this paper, we present a new dose-finding method that extends the continual reassessment method to account for the location of multiple MTDCs. Operating characteristics are demonstrated through simulation studies and are compared with existing methodology. Some brief discussion of implementation and available software is also provided. Copyright © 2016 John Wiley & Sons, Ltd.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.